


## TRANSITION FROM PCV13 (PREVENAR 13) TO PCV20 (PREVENAR 20)



### Background & Rationale

- **What causes Pneumococcal disease?**
  - Streptococcus pneumoniae
- **What do we aim to prevent with pneumococcal vaccines?**
  - Invasive pneumococcal disease (IPD) - bacteremia, sepsis, meningitis
  - Non-invasive pneumococcal disease - community acquired pneumonia, otitis media, sinusitis
- **Who is at risk for IPD?**
  - Adults ≥ 65 years
  - Children < 2 years
  - Chronic medical conditions
  - Immunocompromised individuals
- **PCV 20 replaces PCV 13 in our adult pneumococcal conjugate vaccine formulary due to broader serotype coverage.**

Serotypes contained in current and new pneumococcal vaccines

	1	3	4	5	6A	6B	7F	9V	14	18C	19A	19F	23F	8	10A	11A	12F	15B	22F	33F	2	9N	17F	20	
PCV13	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓												
PCV20 <i>NEW</i>	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
PPSV23	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

\*PCV: Pneumococcal Conjugate Vaccine  
PPSV: Pneumococcal Polysaccharide Vaccine

PCV contains polysaccharide (sugar molecules) from outside of pneumococcal bacteria have been attached (conjugated) to a protein. It elicits a T-cell dependent immune response and is more immunogenic than PPSV23. It induces long-term protection, immunologic memory and longer duration of protection, with a better immunologic response when used for priming.

On the other hand, PPSV contains polysaccharide molecules that elicits T cell independent immune responses. It is a poor inducer of immunologic memory and it is associated with immunological hyporesponsiveness to subsequent vaccinations. It is often used for broader, supplemental coverage

### Vaccination Schedule for Adults

Each dose is 0.5mL via intramuscular (IM)

Prior Vaccines	Healthy Adults (≥ 50 years old)	Immunocompromising conditions, cochlear implants or CSF leaks	Chronic Medical Conditions (Ages 19+)
None			PCV 20
PCV 13 only		≥1 year →	PCV 20
PPSV 23 only		≥1 year →	PCV 20
PCV 13 & PPSV23 < 65 yrs		≥5 years →	PCV 20
PCV 20 at any age	No vaccines recommended, schedule is completed		

- Immunocompromised includes HIV, cancer, asplenia, chronic kidney disease or immunosuppressive drugs.
- Chronic medical conditions includes chronic heart/lung/liver disease, diabetes, alcoholism, and cigarette smoking.
- Clinical data for immunocompromised or high risk populations are limited, its use is supported by extensive experience with Prevenar 13.

# Update in Post Splenectomy patients

Pneumococcal Conjugate (Prevenar 20®) 0.5mL  
 Meningococcal A,C,Y,W 135 (Menveo®) 0.5mL  
 Haemophilus influenzae Type B conjugate (Hiberix®) 0.5mL

↓  
**8 weeks**

Meningococcal A,C,Y,W 135 (Menveo®) 0.5mL

↓  
**Revaccination every 5 years**

Meningococcal A,C,Y,W 135 (Menveo®) 0.5mL

Additional vaccine: Influenza vaccine annually

## Prevenar 20:

To buy at SF Pharmacy  
 RM 242  
 or UKMSC Pharmacy  
 RM 280

## Menveo:

Free for post splenectomy patients

## Hiberix:

To buy at UKMSC Pharmacy  
 RM 82.20



- **Timing of pneumococcal vaccine in splenectomy patient:** 2 weeks prior to elective surgery/ at least 2 weeks post-op or upon discharge for emergency surgery

## Prevenar 20 in Special Population

- **Pregnancy**
  - Limited data in pregnant women
  - Animal studies showed no fetal harm
- **Breastfeeding**
  - Unknown if vaccine passes into breast milk
  - No data on infant effects
  - Weigh benefits of breastfeeding and vaccination



## Vaccination Schedule for Neonates

Each dose is 0.5mL via intramuscular (IM)

Vaccine	Dosing Schedule
<b>Remain status quo:</b> <b>Prevenar 13</b>	<ul style="list-style-type: none"> <li>• 3-dose series: 4, 6 and 15 months of age</li> <li>• 4-dose series*: includes an additional 1 dose at 6 weeks - 2 months of age</li> </ul>

- 4 dose series only for selected patient in NICU.
- The use of Prevenar 20 in infants younger than 6 weeks has not been established.
- Only available in UKMSC RM 230.00

## References:

1. Prevenar 20 Product Monograph (2025), NPRA Malaysia.
2. Adult immunization schedule notes (2025) Centers for Disease Control and Prevention. (Accessed: 10 February 2026).
3. Splenectomy Vaccination & Antimicrobial Prophylaxis (Adult asplenic & hyposplenic patients) Clinical Guideline (2019), South Australia.
4. Australian Immunization Handbook (2025), Australia.
5. National Antimicrobial Guideline (NAG) (2025). Ministry of Health, Malaysia
6. Sanford Guide Antimicrobial Therapy (2025). USA

Editor:

Nur Hafiza Saripin  
 Leanne Lew Hwui Ser  
 Michelle Tan Hwee Pheng

A publication of Drug Information Centre  
[druginfo@hctm.ukm.edu.my](mailto:druginfo@hctm.ukm.edu.my)

To download HCTM Formulary App, click below



**CEKAP, PANTAS, MESRA**  
**ILMU, MUTU DAN BUDI**



**MALAYSIA MADANI**  
*kesejahteraan*

**SUSTAINABLE DEVELOPMENT GOALS**

